|

|
Nutrilib.com
A comprihensive source of nutritional information
|
|
DRUG INTERACTIONS Drug Interactions
Since entecavir is primarily eliminated by the kidneys (see CLINICAL PHARMACOLOGY: Metabolism and Elimination), coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug. Coadministration of entecavir with lamivudine, adefovir dipivoxil, or tenofovir disoproxil fumarate did not result in significant drug interactions. The effects of coadministration of BARACLUDE with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when BARACLUDE is coadministered with such drugs.
|
OVERDOSAGE
There is no experience of entecavir overdosage reported in patients. Healthy subjects who received single entecavir doses up to 40 mg or multiple doses up to 20 mg/day for up to 14 days had no increase in or unexpected adverse events. If overdose occurs, the patient must be monitored for evidence of toxicity, and standard supportive treatment applied as necessary.
Following a single 1-mg dose of entecavir, a 4-hour hemodialysis session removed approximately 13% of the entecavir dose.
|
CONTRAINDICATIONS
BARACLUDE is contraindicated in patients with previously demonstrated hypersensitivity to entecavir or any component of the product.
|
|
Page last updated: 2006-06-08
|
|
-- advertisement --
|